Observational studyBlood cancer journal2026
Temporal trends and demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER database (1999-2022).
Observational study in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a plasma cell malignancy associated with significant morbidity and mortality. Recent advances in the treatment modalities have improved survival, but less is known about MM incidence and associated demographic disparities across sex, age, and racial/ethnic groups. We conducted a retrospective population-based analysis using the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2022. Annual crude and age-adjusted incidence rates (per 100,000 population) were analyzed overall and stratified by age, sex, race, and ethnicity. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) with 95% confidence intervals. Age-specific incidence patterns were evaluated using crude rates, and differences between consecutive age groups were assessed descriptively. Between 1999 and 2022, the age-adjusted incidence of MM increased by approximately 23%. Incidence was higher in males than females (APC: males 1.19%, females 1.19%). Black or African American individuals had the highest incidence, with greatest annual increase (APC 1.40%), whereas White individuals had a more gradual rise (APC 1.07%). Non-Hispanic individuals had higher incidence compared with Hispanic individuals. Incidence increased markedly with advancing age, peaking at 80-84 years before declining significantly among those aged ≥85 years. MM incidence has increased steadily in the United States over the past two decades, with males, older adults, Black or African American individuals, and non-Hispanic populations bearing a disproportionate disease burden. This reflects the need for further research into demographic disparities in multiple myeloma incidence. Clinical Trial Registration: This study was not a clinical trial and therefore was not registered in a clinical trial registry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.